Overview
With no current viable treatment options, NASH remains a debilitating disease that hundreds of companies are chasing after. Due to its non-existent list of treatment options that are effective, there is a massive demand. Growing at a CAGR of over 60%, companies are pushing to be first to market to capitalize in this space. Intercept Pharmaceuticals (ICPT) is the current market leader, recently publishing positive Phase III data with one out of its two endpoints met. While only needing to meet one, will not having both endpoints in its corner be hindering when it